WO2022254316A1 - 皮膚外用治療關節退化及骨質疏鬆症的天然提取物與方法 - Google Patents
皮膚外用治療關節退化及骨質疏鬆症的天然提取物與方法 Download PDFInfo
- Publication number
- WO2022254316A1 WO2022254316A1 PCT/IB2022/055058 IB2022055058W WO2022254316A1 WO 2022254316 A1 WO2022254316 A1 WO 2022254316A1 IB 2022055058 W IB2022055058 W IB 2022055058W WO 2022254316 A1 WO2022254316 A1 WO 2022254316A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- active ingredient
- cells
- mixture
- cell
- skin
- Prior art date
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 100
- 230000007850 degeneration Effects 0.000 title claims abstract description 33
- 230000000699 topical effect Effects 0.000 title claims abstract description 21
- 239000000284 extract Substances 0.000 title claims description 94
- 238000000034 method Methods 0.000 title abstract description 30
- 229940088597 hormone Drugs 0.000 claims abstract description 40
- 239000005556 hormone Substances 0.000 claims abstract description 40
- 230000037118 bone strength Effects 0.000 claims abstract description 33
- 244000284012 Vetiveria zizanioides Species 0.000 claims description 62
- 239000000203 mixture Substances 0.000 claims description 62
- 235000007769 Vetiveria zizanioides Nutrition 0.000 claims description 53
- 239000004480 active ingredient Substances 0.000 claims description 43
- 241000196324 Embryophyta Species 0.000 claims description 41
- 230000001105 regulatory effect Effects 0.000 claims description 22
- 244000000626 Daucus carota Species 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 241000209504 Poaceae Species 0.000 claims description 12
- 206010023230 Joint stiffness Diseases 0.000 claims description 11
- 235000002767 Daucus carota Nutrition 0.000 claims description 10
- 230000005856 abnormality Effects 0.000 claims description 9
- 150000002632 lipids Chemical class 0.000 claims description 2
- 241000208173 Apiaceae Species 0.000 claims 4
- 230000003054 hormonal effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 258
- 208000002193 Pain Diseases 0.000 abstract description 14
- 230000036407 pain Effects 0.000 abstract description 14
- 239000000419 plant extract Substances 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 description 469
- 239000003153 chemical reaction reagent Substances 0.000 description 242
- 241000700159 Rattus Species 0.000 description 107
- 102000004257 Potassium Channel Human genes 0.000 description 102
- 108020001213 potassium channel Proteins 0.000 description 102
- 238000002474 experimental method Methods 0.000 description 90
- 210000003491 skin Anatomy 0.000 description 76
- 230000001965 increasing effect Effects 0.000 description 69
- 239000003642 reactive oxygen metabolite Substances 0.000 description 68
- 210000000988 bone and bone Anatomy 0.000 description 64
- 230000035899 viability Effects 0.000 description 62
- 230000003833 cell viability Effects 0.000 description 52
- 210000002966 serum Anatomy 0.000 description 51
- 239000003814 drug Substances 0.000 description 48
- 229940079593 drug Drugs 0.000 description 41
- 230000002829 reductive effect Effects 0.000 description 40
- 239000011575 calcium Substances 0.000 description 37
- 229910052791 calcium Inorganic materials 0.000 description 37
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 36
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 36
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 36
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 36
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 34
- 229960005309 estradiol Drugs 0.000 description 34
- 229930182833 estradiol Natural products 0.000 description 34
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 33
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 33
- 229910052760 oxygen Inorganic materials 0.000 description 33
- 239000001301 oxygen Substances 0.000 description 33
- 238000011160 research Methods 0.000 description 32
- 230000003078 antioxidant effect Effects 0.000 description 31
- 108010078554 Aromatase Proteins 0.000 description 27
- 102000014654 Aromatase Human genes 0.000 description 27
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 27
- 229910001424 calcium ion Inorganic materials 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 25
- 230000006870 function Effects 0.000 description 25
- 239000000126 substance Substances 0.000 description 25
- 230000003834 intracellular effect Effects 0.000 description 24
- 210000002889 endothelial cell Anatomy 0.000 description 23
- 230000037182 bone density Effects 0.000 description 22
- 230000002485 urinary effect Effects 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 229940109239 creatinine Drugs 0.000 description 18
- 230000006378 damage Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 206010017076 Fracture Diseases 0.000 description 17
- 239000003963 antioxidant agent Substances 0.000 description 17
- 235000006708 antioxidants Nutrition 0.000 description 17
- 239000006143 cell culture medium Substances 0.000 description 17
- 230000008859 change Effects 0.000 description 17
- 229940011871 estrogen Drugs 0.000 description 17
- 239000000262 estrogen Substances 0.000 description 17
- 210000003606 umbilical vein Anatomy 0.000 description 17
- 230000003247 decreasing effect Effects 0.000 description 16
- 230000002159 abnormal effect Effects 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 239000007640 basal medium Substances 0.000 description 14
- 201000008482 osteoarthritis Diseases 0.000 description 14
- 210000005167 vascular cell Anatomy 0.000 description 14
- 238000005899 aromatization reaction Methods 0.000 description 13
- 230000033228 biological regulation Effects 0.000 description 13
- 239000005515 coenzyme Substances 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 13
- 235000015112 vegetable and seed oil Nutrition 0.000 description 13
- 239000008158 vegetable oil Substances 0.000 description 13
- 208000010392 Bone Fractures Diseases 0.000 description 12
- 230000037396 body weight Effects 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 210000002700 urine Anatomy 0.000 description 12
- 208000006820 Arthralgia Diseases 0.000 description 11
- 230000010534 mechanism of action Effects 0.000 description 11
- 230000001009 osteoporotic effect Effects 0.000 description 11
- 230000001133 acceleration Effects 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 238000009806 oophorectomy Methods 0.000 description 10
- 108090000862 Ion Channels Proteins 0.000 description 9
- 102000004310 Ion Channels Human genes 0.000 description 9
- 210000000577 adipose tissue Anatomy 0.000 description 9
- 230000004097 bone metabolism Effects 0.000 description 9
- 230000002708 enhancing effect Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 102000003734 Voltage-Gated Potassium Channels Human genes 0.000 description 8
- 108090000013 Voltage-Gated Potassium Channels Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 239000000039 congener Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 230000004792 oxidative damage Effects 0.000 description 8
- 230000035882 stress Effects 0.000 description 8
- 238000000692 Student's t-test Methods 0.000 description 7
- 238000013329 compounding Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 210000001503 joint Anatomy 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- 210000000963 osteoblast Anatomy 0.000 description 7
- -1 pancreas Chemical compound 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 230000008439 repair process Effects 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- 238000012353 t test Methods 0.000 description 7
- 208000006386 Bone Resorption Diseases 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 230000024279 bone resorption Effects 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000000689 upper leg Anatomy 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 230000003394 haemopoietic effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000002997 osteoclast Anatomy 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000010428 Muscle Weakness Diseases 0.000 description 4
- 206010028372 Muscular weakness Diseases 0.000 description 4
- 238000001994 activation Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 230000003412 degenerative effect Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000002222 downregulating effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000004394 hip joint Anatomy 0.000 description 4
- 210000000629 knee joint Anatomy 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000009245 menopause Effects 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 229910052716 thallium Inorganic materials 0.000 description 4
- 229940122361 Bisphosphonate Drugs 0.000 description 3
- 206010030247 Oestrogen deficiency Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 3
- 229960005471 androstenedione Drugs 0.000 description 3
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 3
- 230000002968 anti-fracture Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000005842 biochemical reaction Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000004663 bisphosphonates Chemical class 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000012094 cell viability reagent Substances 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 210000002149 gonad Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000002780 ion channel assay Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000003270 steroid hormone Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000007126 Codonopsis pilosula Species 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 244000203593 Piper nigrum Species 0.000 description 2
- 235000008184 Piper nigrum Nutrition 0.000 description 2
- 238000012356 Product development Methods 0.000 description 2
- 231100000991 Reactive Oxygen Species (ROS) Photosafety Assay Toxicity 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- 241000206572 Rhodophyta Species 0.000 description 2
- 244000152045 Themeda triandra Species 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 229960004343 alendronic acid Drugs 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229940008396 carrot extract Drugs 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 229960001251 denosumab Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000004821 effect on bone Effects 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- 239000003256 environmental substance Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 229960003399 estrone Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 208000012285 hip pain Diseases 0.000 description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- 230000036632 reaction speed Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008844 regulatory mechanism Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- DIZZDZCUMBBRSG-UHFFFAOYSA-J tetrasodium;2-[[5-[3-[3-[[bis(carboxylatomethyl)amino]methyl]-4-hydroxy-2-methyl-5-propan-2-ylphenyl]-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]-2-hydroxy-6-methyl-3-propan-2-ylphenyl]methyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CC1=C(O)C(C(C)C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C(=C(CN(CC([O-])=O)CC([O-])=O)C(O)=C(C(C)C)C=2)C)=C1C DIZZDZCUMBBRSG-UHFFFAOYSA-J 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 1
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 1
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 1
- BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241001633574 Adenophora stricta Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000005255 Allium cepa Nutrition 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 244000028550 Auricularia auricula Species 0.000 description 1
- 235000000023 Auricularia auricula Nutrition 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000005702 Calcium-Activated Potassium Channels Human genes 0.000 description 1
- 108010045489 Calcium-Activated Potassium Channels Proteins 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 235000009103 Canarium album Nutrition 0.000 description 1
- 244000012254 Canarium album Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 235000002567 Capsicum annuum Nutrition 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 235000002555 Citrus medica var sarcodactylis Nutrition 0.000 description 1
- 240000007126 Citrus medica var. sarcodactylis Species 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 235000009088 Citrus pyriformis Nutrition 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000219112 Cucumis Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 235000009849 Cucumis sativus Nutrition 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- 241000931332 Cymbopogon Species 0.000 description 1
- FEPOUSPSESUQPD-UHFFFAOYSA-N Cymbopogon Natural products C1CC2(C)C(C)C(=O)CCC2C2(C)C1C1(C)CCC3(C)CCC(C)C(C)C3C1(C)CC2 FEPOUSPSESUQPD-UHFFFAOYSA-N 0.000 description 1
- 244000166675 Cymbopogon nardus Species 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 241000208175 Daucus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000919395 Homo sapiens Aromatase Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 244000302544 Luffa aegyptiaca Species 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 235000019083 Osmanthus fragrans Nutrition 0.000 description 1
- 244000242564 Osmanthus fragrans Species 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 102100034354 Potassium voltage-gated channel subfamily KQT member 2 Human genes 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 235000000659 Rosa rugosa Nutrition 0.000 description 1
- 240000006066 Rosa rugosa Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000908178 Tremella fuciformis Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 1
- 229960004191 artemisinin Drugs 0.000 description 1
- 229930101531 artemisinin Natural products 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- ZAZYUFWBENXXPV-UHFFFAOYSA-N calcium gold Chemical compound [Ca].[Au] ZAZYUFWBENXXPV-UHFFFAOYSA-N 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000002434 celiac artery Anatomy 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000001359 coriandrum sativum l. oleoresin Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000002834 estrogen receptor modulator Substances 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003574 free electron Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QCAWEPFNJXQPAN-UHFFFAOYSA-N methoxyfenozide Chemical compound COC1=CC=CC(C(=O)NN(C(=O)C=2C=C(C)C=C(C)C=2)C(C)(C)C)=C1C QCAWEPFNJXQPAN-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- QVGXLLKOCUKJST-AKLPVKDBSA-N oxygen-19 atom Chemical compound [19O] QVGXLLKOCUKJST-AKLPVKDBSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 239000000447 pesticide residue Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006950 reactive oxygen species formation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000024351 regulation of hormone secretion Effects 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000004154 testing of material Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
Definitions
- Single chemical composition is the main direction of medicine research field, and mechanism of action is definite, and most modern medicines are all single chemical composition medicines, and the medicine of multimaterial and multichemical composition (as composite composition medicine and traditional Chinese medicine) because raw material , molecular weight, molecular structure, boiling point, optical rotation, saponification value, iodine value, disintegration, solubility and volatility and other physical and biochemical indicators are different, and there are chemical complexity and variability that are difficult to grasp. , the more substances and chemical compounds, the more complex the molecular physical and biochemical reactions between them, and the more difficult to predict and grasp the results, which makes the research of compound drugs much more difficult than that of single chemical components.
- An embodiment of the present invention includes a product for external use on the skin mainly made of natural extracts to treat and improve joint degeneration and osteoporosis, help ribs to restore mobility and eliminate pain.
- natural extracts applied externally through the skin can improve joint degeneration and osteoporosis, increase bone strength, help ribs regain mobility and relieve pain.
- the natural extract applied externally through the skin and rubbed on the joints can not only improve the symptoms of degenerative arthritis and osteoporosis of the joints, but also relieve or mediate female menopause Resulting pain and symptoms, return to mobility.
- the natural extract of the present invention includes active ingredients Gramineae (Gramineae) vetiveria zizanioides and plants of the same family, such as vetiver (chrysopogon zizanioides) or Andropogon zizanioides extract (hereinafter collectively referred to as bluegrass).
- the natural extract of the present invention includes an active ingredient of Apiaceae carrot (Daucus carota) extract.
- the natural extract of the present invention includes bluegrass With carrot extract.
- the external use of skin can be absorbed through the skin to avoid the destruction of digestive juice and the first-pass effect of the liver. It can treat abnormal hormones, make estradiol return to normal, and can treat the abnormal estradiol of osteoporosis. Restore the level before osteoporosis, prevent bone calcium loss and transfer to blood and urine, improve bone strength, prevent fractures and treat osteoporosis. Simple illustration
- Fig. 1 is a bar graph showing rat body weight before drug treatment in animal experiments.
- Fig. 2 is a bar graph showing the body weight of rats on day 1 after drug treatment in animal experiments.
- Fig. 3 is a bar graph showing the body weight of rats in 20 days after drug treatment in animal experiments.
- Fig. 4 is a bar graph showing the effect of SDTL-E on serum alkaline phosphatase in ovariectomy model rats in animal experiments.
- Material is made up of different molecule and molecular structure, and each material has different molecular formula, spatial structure and functional effect, and in all material spaces, the space inside and outside of material or molecular intersection space and produced Functional effect is a variable and ratio relationship, and its ratio is changed by other factors involved in the ratio, which will cause different functional changes and results, the type and quantity of compound chemical components in the same environmental space
- the mutual ratio is a dynamic and static balance relationship of ratio, and the mutual ratio balance has an important influence on the function of the substance and the disappearance of the function, and the strength of the function.
- bone is one of the main organs and tissues of vertebrate organisms, one of functions is to support, protect the body and make the organism maintain its ability to move through joints and muscles, nerve tissue, and bones have functions such as storing minerals, mainly composed of Composed of bone, bone marrow, and periosteum, articulation is a part that can move and change angles between bones.
- cartilage, articular cysts, ligaments, and synovial fluid in between. All bone and joint dysfunction diseases will lead to biological Decreased or complete loss of movement and activity (including the human body).
- Osteoporosis and degenerative arthritis also known as degenerative arthritis
- degenerative arthritis are one of the most important diseases in orthopedics and motor impairment. There are a large number of patients all over the world.
- Hip pain increase bone strength and enhance the ability to resist fractures.
- the embodiment of the present invention can quickly alleviate, eliminate and treat the clinical symptoms caused by bone and joint degeneration and looseness, regardless of age, race and gender, and can be applied to various living things, including but not limited to cats, dogs and other animals, and is easy to operate .
- the extract of this method can be obtained by various processes, including distillation, pressing and supercritical extraction.
- the present invention can be extended to be applied in various fields, including daily chemicals, cosmetics, skin care, health care and pharmaceuticals, and can be applied in various forms and dosage forms, including skin external application and emulsion dosage forms.
- Osteoarthritis and osteoporosis have numerous patients all over the world, and develop towards younger age, the clinical symptoms of inconvenient movement such as arthritic joint abnormal sound, joint weakness, muscle weakness, pain, difficulty in squatting down, unable to go up and down stairs and Osteoporosis such as bone density, pain and other clinical symptoms are ubiquitous, causing serious troubles and heavy burdens to many patients, families and society.
- Osteoporosis is a metabolic disease. Patients are prone to pain, fractures and complications due to reduced bone density. Calcium supplementation, vitamin D supplementation and exercise are one of the countermeasures, but the effect is limited.
- Diclofenac The inflammatory drug Diclofenac (Diclofenac) is used for the in vitro treatment of arthritis and osteoporosis, but it is contraindicated in pregnant women and has many side effects.
- the U.S. Food and Drug Administration (FDA) pregnancy drug system classifies this drug as C moderate risk and D high risk.
- the side effects include stomach discomfort, nausea and vomiting, heartburn, diarrhea, constipation, flatulence, headache, drowsiness, dizziness, etc., while other drugs have long treatment cycle, many side effects, replacement page (rule 26) Defects that cannot be used continuously.
- the present invention has small side effects on the human body and animals.
- the only known adverse reaction is that if it is used when sweating, a small amount of localized red spots will appear on the skin due to the one-way perspiration mechanism of the skin. Stop using it for about two days The red dot will disappear by itself.
- Natural plants or extracts are one of the sources of natural pharmaceutical raw materials, and single compounds (such as artemisinin, lutein, elemene, etc.) have been widely used in medicine, beauty and related industries or products, and are widely used Applied to the production of anti-aging and natural medicines, a single compound can remove harmful substances such as heavy metals and pesticide residues that are harmful to the human body through modern technology during the extraction process, providing better and higher equivalent concentration of drug raw materials, a single compound The function is simpler and clearer, the effect is clearer, and the action target and pharmacology are easier to understand clearly. Natural plants and organisms have better bioacceptance and compatibility, and the compounds in natural extracts can inhibit different cells, action sites, and dysfunctional enzymes (Enzymes) due to molecular clustering. Elevation and other adjustments.
- Enzymes enzymes
- Gramineae Vetiveria zizanioides and plants of the same family such as vetiver (chrysopogon zizanioides) or Andropogon zizanioides extract
- vetiver chlorrysopogon zizanioides
- Andropogon zizanioides extract have a pain-relieving effect on knee joint pain (approximately Less than 2 hours), it also improves joint stiffness and mobility.
- the carrot Daucus carota extract also had an improving effect on joint stiffness and pain.
- vetiver vetiveria zizanioides and its congeners such as vetiver (chrysopogon zizanioides) or Andropogon zizanioides extract
- carrot Daucus carota extract or compound with other extracts, in order to seek more Better, faster, more obvious functional effects and therapeutic effects.
- the present invention is a kind of with natural plant Vetiveria zizanioides and its congener genera (such as vetiver (chrysopogon zizanioides) or Andropogon zizanioides extract external skin treatment and improvement of joint degeneration and bone quality
- the extract can be mixed with other media or substances, including oil (but not limited to oil, extract, solvent), in one embodiment, the weight of the extract and solvent is 1 ⁇ 9: 9 ⁇ 1 Ratio range, in one embodiment, the weight ratio range is 1 ⁇ 7: 3 ⁇ 9, in one embodiment, the weight ratio range is 1 ⁇ 5:5 ⁇ 9, external use on the skin can relieve joint pain, stiffness and other effects.
- the present invention is a kind of natural plant Vetiveria zizanioides and its replacement page (rule 26)
- the formulation of extracts from the same family such as vetiver (chrysopogon zizanioides) or Andropogon zizanioides) combined with carrot Daucus carota extract can treat and improve joint degeneration and osteoporosis with external application on the skin.
- the formulation is composed of vetiver vetiveria zizanioides and its congeners (such as the extract of vetiver (chrysopogon zizanioides) or Andropogon zizanioides) as the main component, in one embodiment, compounded with carrot Daucus carota extract, in one embodiment, the weight ratio range between the two extracts is 1 ⁇ 9: 2 ⁇ 9; in one embodiment, the ratio range is 1.5 ⁇ 7.5: 2.5 ⁇ 8.5; in one embodiment, the ratio range is 1 ⁇ 5: 4.5 ⁇ 8.
- the abnormal estrogen and serum alkaline phosphatase content of ovariectomized rat osteoporosis can be restored to the normal level before osteoporosis by skin topical application, and the lack of estrogen causes Osteoporosis has physiological changes, treatment and protection, and can be applied to the treatment of diseases related to bone and joint degeneration and osteoporosis.
- the external application of the present invention can treat the hip joint pain of human osteoporosis and the abnormal noise of joint degeneration, the inability of the joint to bend, the joint weakness, muscle weakness, difficulty in squatting down, difficulty in going up and down the stairs Intensity reduction, is a way to treat disease.
- extract can be obtained with various production techniques, including distillation, extraction, supercritical etc.
- formula can be compounded or melted again with other substances, can be in various forms and dosage forms, such as liquid, emulsion , spray, smear, etc.
- the present invention can improve the clinical symptoms of human degenerative arthritis and osteoporosis, improve joint mobility, increase joint range of motion and reduce joint pain, improve joint abnormal noise, improve joint
- the present invention can regulate hormone levels, and can be applied to improve bone and joint degeneration, osteoporosis, and physical discomfort caused by abnormal hormones.
- Aromatase is called estrogen synthetase (estrogen synthetase) . It can catalyze the aromatization reaction from androgen to estrogen in the process of steroid hormone synthesis, and catalyze the conversion of androstenedione and testosterone to estrogen Ketone and estradiol conversion, aromatase exists in gonad, brain, adipose tissue, blood vessel, skin and bone, and the reaction speed of aromatase can be regulated by coenzyme.
- the present invention uses these two natural extracts in proportion Mixed within the range, as the composite formula in the present invention, it is tried on human body and animals, and according to animal experiments and human body use statistics, it has been proved that the formula of the present invention and the method of use have strong practicability, obvious efficacy, rapid onset, wide range of effects and
- the embodiments of the present invention in animals and human bodies are as follows:
- Hormone deficiency is one of the main causes of causing postmenopausal osteoporosis and joint degeneration, and there are hormone receptors in chondrocytes such as small intestine, osteoblast, osteoclast precursor, bone cell and growth bone plate, Decreased estrogen levels and increased serum alkaline phosphatase levels after menopause are one of the most important causes of joint degeneration and osteoporosis in women, so the mixture formula (hereinafter referred to as SDTL-E) in an embodiment of the method of the present invention is used In the skin of ovariectomized (OVX) osteoporosis model rats, the data changes in rats were observed.
- OVX ovariectomized
- this SDTL-E can improve estrogen in biological rats and reduce rat serum alkaline phosphatase content to normal level, and has balance ovariectomized model rat estrogen and serum alkali sex phosphatase containing
- the selected ovariectomized rat experimental model has rich literature, mature technology, stable and reliable, and is the best model for OVX rat research recommended by the World Health Organization (WHO) and the National Institutes of Health (NIH) .
- WHO World Health Organization
- NASH National Institutes of Health
- the SDTL-E formula is based on the Vetiver extract as the main compound with the red radish Daucus camta extract, in one embodiment, the 2 extracts are separately shaken and stirred > 10 Second, in one embodiment, the weight ratio range between the two extracts is 1 ⁇ 9: 2 ⁇ 9; in one embodiment, the ratio range is 1.5 ⁇ 7.5: 2.5 ⁇ 8.5; in one embodiment, the ratio range 2 ⁇ 5: 4.5 ⁇ 8.
- the two things are mixed in an environment above > 4°C and can be > 40 revs/sec mixed and stirred > 5 seconds (depending on the actual proportioning total weight and finally determining to increase the stirring time) to stand still, and can be mixed with other solvents such as Fat fusion, in one embodiment, is effective in the weight ratio range of 1 ⁇ 9: 9 ⁇ 1 with fat fusion, in one embodiment, the weight ratio range is 1 ⁇ 7: 3 ⁇ 9, in one embodiment Among them, the weight ratio range is 1 ⁇ 5:5 ⁇ 9, and the skin is applied to experimental animals. The results show that it has a down-regulation effect on the early compensatory increase of alkaline phosphatase Alkaline phosphatase (ALP) in model rats.
- ALP alkaline phosphatase
- Estradiol hormone has the effect of increasing, can reduce the hyperabsorption of osteoporotic animals, restore the therapeutic function and balance of estrogen and serum alkaline phosphatase, and protect and treat the pathological changes of osteoporosis caused by estrogen deficiency It can rapidly increase bone strength and increase anti-fracture ability, and can be researched and developed into a drug for treating bone and joint degeneration and osteoporosis. (See Annex 1. Animal Experiments J
- the extract of natural plant Vetiveria zizanioides and its congeners (such as vetiver (chrysopogon zizanioides) or Andropogon zizanioides) is diluted with solvent
- the weight ratio range is 1 ⁇ 5:5 ⁇ 9, as a solvent, it has the effect of slowing down and improving joint pain and stiffness.
- it is used in the knee of human degenerative arthritis 2 times a day for the skin, 0.4m I each time, 8 people tried it out, and counted after 2 hours of use.
- 4 of them had a tendency to alleviate joint pain and stiffness (the trend rate was 50%) and could maintain About 2 hours, in one embodiment, it shows that the single extract of vetiver can improve the symptoms of joint degeneration, pain and stiffness.
- the SDTL-E formula composed of vetiver and carrot 2 extracts was used as an external agent for human skin, and it was used on the knee joint skin of patients with joint degeneration (voluntary users), and observed effect and make statistics.
- the SDTL-E formula is compounded by Vetiver vetiveria zizanioides and its congener genera (such as vetiver (chrysopogon zizanioides) or Andropogon zizanioides and Daucus carota extract, in a
- the two extracts are separately shaken and stirred for more than 10 seconds before compounding.
- the weight ratio between the two extracts is 1 ⁇ 9: 2 ⁇ 9; in one embodiment, the ratio is 1.5 ⁇ 7.5: 2.5 ⁇ 8.5; In one embodiment, the ratio range is 2 ⁇ 5: 4.5 ⁇ 8.
- the two substances are mixed at > 4 ° C and > 40 rpm > 5 second (depending on the actual total weight to finally decide to increase the stirring time) and leave it alone, in one embodiment, then blend with the fat, in one embodiment, blend with the fat in the weight ratio range of 1 ⁇ 9: 9 ⁇ 1 , in one embodiment, the weight ratio range is 1 ⁇ 7: 3 ⁇ 9, in one embodiment, the weight ratio range is 1 ⁇ 5:5 ⁇ 9, in one embodiment, the skin is applied externally to the human body, SDTL-E is tried out with 23 people who suffer from knee joint disorders age 50-96 years old, in one embodiment, use 2 times a day, each time 0.4
- the invalid ones in the table may be users who are not osteoporosis or other inflammatory patients.
- vetiver chrysopogon zizanioides
- Andropogon zizanioides have the effect of improving joint pain and stiffness
- the SDTL-E compound formula is faster and more effective than a single vetiver extract
- the hormone has the effect of increasing, and has the effect of reducing the serum alkaline phosphatase content.
- several cases of skin have shown that a single vetiver vetiveria zizanioides and its congeners (vetiver (chrysopogon zizanioides) or Andropogon zizanioides) have the effect of improving joint pain and stiffness
- the SDTL-E compound formula is faster and more effective than a single vetiver extract
- the hormone has the effect of increasing, and has the effect of reducing the serum al
- the present disclosure provides a solution to the long-standing need described above.
- aspects of the present invention overcome prior reliance on the use of non-natural or chemically based mixtures to treat and improve joint degeneration and osteoporosis, aid in regaining mobility, and relieve pain.
- Rats were randomly assigned to sham operation control group (control group), ovariectomized rat osteoporosis model control group (model group, ovariectomized rat osteoporosis model SDTL-E treatment group 8011 ⁇ £ group>, model group and SDTL -E group received ovariectomy, and the control group received surgery without ovariectomy.
- control group ovariectomized rat osteoporosis model control group
- model group ovariectomized rat osteoporosis model SDTL-E treatment group
- SDTL-E treatment group were compared with those of the control group. Ratio, bone density difference is significant, the data show that osteoporosis modeling is successful.
- the skin of the control group and the model group is externally applied with vegetable oil liquid
- the skin of SDTL-E group is externally applied with oily liquid SDTL-E, twice a day for 20 days .
- the experimental results showed that the serum estradiol value in the model group was still significantly lower , the serum alkaline phosphatase (ALP) activity, serum calcium, and urine calcium were still significantly higher, the bone mechanical indexes were still significantly lower, and the number of trabecular bone decreased. , Thinning, sparse and broken.
- ALP serum alkaline phosphatase
- estradiol value in the SDTL-E group was significantly restored to the level of the (sham operation) control group, the ALP activity, serum calcium, and urine calcium were significantly reduced to the level of the (sham operation) control group, and the bone mechanical indexes of torsional force, torque and shear The shear modulus was increased, the shear stress was significantly increased to the level of the (sham-operated) control group, and the number of trabeculae was slightly increased.
- Drug therapy is mainly divided into two categories: oral and injection.
- One is to reduce the rate of bone resorption, including bisphosphonates (Bisphosphonates), estrogen (Estrogen) and denosumab (Denosumab).
- bisphosphonates Bisphosphonates
- Estrogen Estrogen
- denosumab Denosumab
- drugs include parathyroid hormone analogs (Parathyroid Hormone Analogs) and the like.
- 3-month-old Sprague Dawley female rats were purchased from the Guangdong Provincial Medical Experimental Animal Center (Foshan, Guangdong, China). Rats were fed SPF-grade granular mouse feed, and they were free to ingest bottled tap water. The feeding conditions were at a temperature of 20°C The humidity is 80%, and the light and dark are 12 hours each. After feeding for 15 days, the rats are randomly assigned to the following three treatment groups (10-12 rats in each group): (1) sham operation control group (control group); (2) Ovariectomized rat model control group (model group; C3) Ovariectomized rat osteoporosis model SDTL-E treatment group (CSDTL-E group).
- Ovariectomized rat model and treatment program model group and SDTL-E treatment group were anesthetized with Bacillus (Sinopharm Chemical Reagents Co. Ltd, Shanghai, China) and operated aseptically.
- the abdominal cavity was opened 4 cm below the xiphoid process, about 1.5 cm, Pull out the fat pad to find the ovaries on both sides and remove them, then return the fat pad to suture the abdominal cavity.
- the control group underwent the above surgery without ovary removal. Then intramuscular injection of ampicillin ( ⁇ Sinopharm Chemical Reagents) 100,000 units/rat, continuous injection for 3 days.
- the above-mentioned animals were raised for 3 months, and then the weight was measured and the bone density was detected by dual-energy X-ray.
- Rats in the above three groups were given 3% pentobarbital sodium (36mg/kg) (Sinopharm Chemical Reagents) intraperitoneal injection for anesthesia, and then smeared depilatory agent (sodium sulfide 3g, soap powder 1g, starch 7g, added water to adjust to Paste) about 5 minutes, the hair removal area is about 3cmx4cm. Dosing started 48 hours after hair removal. 100
- ALP test kit (Nanjing Jiancheung Bioengineering Institute, Nanjing, Jiangsu, China) will be used to measure serum ALP activity. According to the supplier's instructions, the serum ALP in the sample reacted with the p-Nitrophenylphosphate substrate (p-Nitrophenylphosphate) provided by the kit to generate a yellow product, which was then analyzed using an S22PC spectrophotometer (Shanghai Lengguang Technology Co. Ltd, Shanghai, China). Absorbance was measured at a wavelength of 415 nm to quantify serum ALP activity. Calcium ion determination Calcium ion test kit (Nanjing Jiancheung Bioengineering Institute) was used to determine serum and urine #5 ion levels.
- the calcium ions in the sample react with the methylthymol blue substrate (Methylthymolblue) provided by the kit to generate a blue product, and then use the S22PC spectrophotometer to measure the absorbance at a wavelength of 610 nm to quantify the serum and urinary calcium levels. Creatinine determination
- the creatinine test kit (Nanjing Jiancheung Bioengineering Institute) was used to determine the urine creatinine level. According to the supplier's instructions, the urine creatinine in the sample was oxidized by the oxidase provided by the kit to produce a purple-red product, and then the absorbance was measured at a wavelength of 546 nm using a S22PC spectrophotometer to quantify the urine creatinine level. Estradiol determination
- the AxSYM Estradiol Kit (Abbott, Chicago, Illinois, U.S. A) was used to measure estradiol levels. According to the supplier's instructions, serum estradiol in the sample was bound to the matrix wells in the form of an antibody-estradiol-alkaline phosphatase conjugate, which was then bound to the substrate 4-methylphenidone phosphate (4- methylumbelliferyl phosphate) was reacted to produce radiance, which was then measured using the ARCHITECT i2000SR immunoassay analyzer (Abbott) to quantify serum estradiol levels.
- Bone Density Test Rats in each group were anesthetized with B, and when the rats were in a stable lethargic state for more than 5 minutes, they were placed under the probe of a Lunar Prodigy dual-energy X-ray absorptiometry (GE Healthcare, Chicago, Illinois, USA) and scanned The speed is 60.0 mmol/L/sec, the step distance is 1.0x1. Ommol/L, the whole body scan is performed after calibration with the small animal software module, and the bone density value BMD (CV ⁇ 1%) is measured. Bone mechanical testing Right tibia CTibia;) for torsional testing (Torsional Testing). Torsion test: The proximal and distal ends of the tibia were embedded in polymethyl methacrylate and placed on the 858 Mini Bionix II material testing system for the torsion test
- Histological examination Remove the soft tissue of the proximal 1/2 of the left femur in rats, fix with freshly prepared 10% neutral formalin (Sinopharm Chemical Reagents) for 24 hours, and then use 0.01M phosphate buffered saline (PBS) (Sinopharm Chemical Reagents) Rinse 3 times, and then use 20% formic acid solution (Sinopharm Chemical Reagents) to remove gold calcium for 6 days. The working solution needs to be replaced every day.
- PBS phosphate buffered saline
- SDTL-E has the effect of reducing serum ALP activity in OVX-induced osteoporosis rats
- ALP assay was used to evaluate the effect of SDTL-E on serum ALP activity of bone metabolism markers.
- the serum ALP activity of the model group was significantly increased to 46.69 ⁇ 13.32 King's unit/100 mL ( ⁇ O.Ol)° SDTL-E group externally applied SDTL -E 20 days later, compared with the model group, the serum ALP activity was significantly reduced by 58.79% to 19.24 ⁇ 6.06 King’s units/100 mL ( ⁇ O.Ol), which was similar to the level of the control group (Appendix 1, Figure 2), showing a significant Regulation and reduction of ALP activity.
- SDTL-E decreased serum ALP activity in OVX-induced osteoporotic rats.
- SDTL-E group (n 10) rats were externally applied to the skin SDTL-E ° externally applied to the skin twice a day for 20 consecutive days.
- ALP assay was used to assess serum ALP activity. Results are expressed as mean ⁇ standard deviation. w/ ⁇ cO.Ol vs model group.
- SDTL-E can increase the serum estradiol level in rats with OVX-induced osteoporosis, and the determination of estradiol was used to evaluate the effect of SDTL-E on serum estradiol. Serum estradiol levels in the control group
- SDTL-E increased serum estradiol levels in OVX-induced osteoporosis rats.
- SDTL-E has the effect of reducing serum and urinary calcium ion levels in OVX-induced osteoporosis rats. Calcium ion determination was used to evaluate the effect of SDTL-E on serum and urinary calcium ion levels of bone metabolism markers. Compared with the serum calcium ion level of 2.28 ⁇ 0.20 mM in the control group, the serum calcium ion level in the model group was significantly increased to 2.70 ⁇ 0.32 mMCPO.Ol;). In the SDTL-E group, SDTL-E was applied externally on the skin.
- the urinary calcium ion level in the model group was significantly increased to 2.45 ⁇ 0.76 mM (P ⁇ 0.01) Compared with the model group, the urinary calcium ion level was significantly reduced by 28.16% to 1.76 ⁇ 0.80 mM ( P ⁇ 0.01 ) (Appendix 1 Figure 4b ), showing that it can significantly prevent the loss and transfer of calcium ions to the urine.
- SDTL-E had no significant effect on the urinary calcium/creatinine ratio in OVX-induced osteoporosis rats.
- Calcium ion determination and creatinine determination were used to measure calcium ion and creatinine to calculate the urinary calcium/creatinine ratio.
- the urinary calcium/creatinine ratio in the model group increased to 0.49 ⁇ 0.29, but there was no statistical significance.
- SDTL-E group SDTL-E was applied externally on the skin, and the ratio of urinary calcium/creatinine decreased to 0.36 ⁇ 0.14 after 20 days, which was similar to that of the control group, and there was no statistical significance compared with the model group (Fig. 5 in Annex 1).
- SDTL-E had no significant effect on the urine creatinine/creatinine ratio in OVX-induced osteoporotic rats.
- SDTL-E group (n 10) rats were externally applied to the skin SDTL-E ° externally applied to the skin twice a day for 20 consecutive days.
- Calcium ion determination and creatinine determination are used to measure the amount of calcium ion and creatinine to calculate the urinary calcium/creatinine ratio. Results are presented as mean ⁇ standard deviation.
- SDTL-E had no significant effect on the bone mineral density of OVX-induced osteoporosis rats. Bone mineral density was detected on the right femur to evaluate the effect of SDTL-E on bone density. Compared with the bone density of the control group (0.22 ⁇ 0.02 g/cm 2 ) , the bone density of the model group was significantly reduced to 0.20 ⁇ 0.01 g/cm 2 CP ⁇ 0.01;).
- SDTL-E group was externally applied SDTL-E to the skin, and the bone mineral density was 0.20 ⁇ 0.01 g/cm 2 after 20 days, which was not significantly different from that in the model group (Appendix 1 Figure 6: ), showing that the SDTL-E group had It has no significant effect on the bone mineral density of osteoporosis model rats.
- SDTL-E improves the bone strength and hardness of OVX-induced osteoporosis rats.
- the model group and the control group apply external vegetable oil to the skin, and the SDTL-E group applies SDTL-E to the skin.
- the results of the bone torsion experiment after 20 days show that the torsional force, torque and The shear stresses were all significantly lower than those in the control group (F ⁇ 0.05) (Appendix I Fig. 7a-c) - although the shear modulus was also lower than the control group, but not statistically significant (Appendix I Fig. 7d).
- the shear stress of the SDTL-E group was significantly increased by 39.93% to 249.502 ⁇ 63.445 Mpa (P ⁇ 0.05), which was close to the shear stress of the control group of 235.540 ⁇ 58.097 Mpa (Appendix 1 Figure 7c).
- the torsional force, torque and shear modulus of the SDTL-E group also increased, but there was no statistical significance.
- Experimental data show that SDTL-E externally applied SDTL-E to the skin, after 20 days, the torsional force, torque and shear modulus are close to those of the control group (Fig. Rat bone strength and stiffness.
- SDTL-E increased bone strength and stiffness in OVX-induced osteoporotic rats.
- SDTL-E group 9
- SDTL-E was applied externally to rat skin. Topical application to the skin twice daily for 20 consecutive days. Bone torsion tests were used to evaluate (a) torsional force, (b) torque, (c) shear stress, and (d) shear modulus. Results are presented as mean ⁇ standard deviation. * ⁇ 0.05 vs model group.
- SDTL-E can improve the bone tissue structure of OVX-induced osteoporosis rats. It can be seen from Figure 8a in Annex 1 that the bone tissue structure of rats in the control group is clear, the bone trabeculae are thicker, the coloring is deeper, the arrangement is denser, and the bone marrow has active hematopoietic function. Trabecular spaces are also smaller. As can be seen in Figure 8b of Annex 1, the number of trabeculae in rats in the model group
- Attachment 1 Figure 8c shows that compared with normal rats in the control group, SDTL-E group rats have thinner bone trabeculae, sparse arrangement, lighter fracture and coloration, widened bone trabecular gaps, decreased blood red bone marrow, and low hematopoietic function , adipose tissue increased, but also showed a slight increase in the number of trabecular bone and a thickening trend compared with model rats, so it is necessary to extend the use of SDTL-E for the next experiment.
- SDTL-E improves bone tissue structure in OVX-induced osteoporotic rats. Vegetable oil was applied externally to the skin of rats in the model group and the control group. SDTL-E was applied externally to the skin of rats in SDTL-E group. Topical application to the skin twice daily for 20 consecutive days. The left femoral bone tissue was stained with HE, and then observed under a 200X magnified optical microscope. Above are representative staining images of rats in (a) control group (b) model group and (c) SDTL-E group.
- Bone strength is positively correlated with the bone's ability to resist fracture.
- bone density a commonly used bone strength marker, was used to study the effect of SDTL-E on the bone strength of OVX rats.
- the bone density of OVX rats in the model group was significantly lower than that in the control group, and the osteoporosis model was successful.
- Osteoporosis reduces the number of trabecular bones, trabecular thickness, and degree of connectivity all affect bone strength.
- SDTL-E externally applied to OVX rats for 20 days restored bone strength, there was no significant change in bone density, indicating that the rapid increase in bone strength was not due to the increase in bone density when SDTL-E was applied externally for 20 days, but may be due to other rapid changes in bone density.
- Strength mechanism of action The microscopic observation results of this study showed that compared with the control rats, the bones of OVX- rats in the model group and SDTL-E group were smaller.
- Aromatase known as estrogen synthetase
- aromatase exists in gonads, brain, adipose tissue, blood vessels, skin and bones, and the reaction speed of aromatase can be regulated by coenzyme.
- bisphosphonate-related drugs (Alendronate Sodium, Alendronate Sodium) can be administered orally for 6 months ( ⁇ 180 days) before the bone strength can be significantly increased and returned to normal levels. It takes 0 ⁇ rt eO ®> 12 weeks to 84 days) before the bone strength increases significantly and returns to normal level, and the estrogen receptor modulator-related drug raloxifene, Raloxifene;) is administered orally for 4 weeks (: ⁇ 28 days > There is no significant increase in bone strength.
- This study shows that the SDTL-E external application of plant ingredients quickly restores estradiol levels, ALP activity, and serum calcium levels through endogenous regulation, and increases the number of trabecular bone and bone density.
- Aromatase is encoded by the gene CYP19A1 in the human body and exists in cytochrome P450 In the enzyme system,
- estrogen synthetase also known as estrogen synthetase ( estrogen synthetase ) can catalyze the aromatization reaction from androgen to estrogen in the process of steroid hormone synthesis, catalyze the conversion of androstenedione and testosterone to estrone and estradiol, aromatase It exists in gonads, brain, adipose tissue, blood vessels, skin and bones, and the speed of aromatase reaction can be regulated by coenzyme.
- SDTL-E has a coenzyme-like effect, and its SDTL-E has the function of aromatization acceleration coenzyme cluster [Aromatization Acceleration Coenzyme Cluster (A ACC)], which may be through the activation of aromatase (Aromatase).
- a ACC aromatization Acceleration Coenzyme Cluster
- Response Enzyme catalysis regulates hormone levels, such as estradiol and ALP activity, serum calcium, urinary calcium, etc., promotes the activity of osteoblasts and inhibits the activity of osteoclasts.
- oil-soluble reagents A, B, C, and D were more capable of improving and enhancing the viability of damaged cells than water-soluble reagents E, F, G, and H.
- A, B, D The higher the concentration of oil-soluble reagents, the more obvious the effect of increasing the vitality of damaged cells, and the most effective peak amount is when the concentration reaches 0.1%-0.9%.
- reagent A has the highest and most obvious ability to improve and enhance the viability of damaged cells, and the concentration of A at 0.1%-0.9% significantly increases the viability of damaged cells, reaching 259% (p ⁇ 0.05).
- each reagent group had little effect on the viability of normal cells, and the data had no statistical significance.
- the oil-soluble reagents in each reagent group were stronger than the water-soluble reagents in improving the viability of damaged cells, and the 0.1%-0.9% concentration of A reagent had the highest and most significant effect on improving and enhancing the viability of damaged cells.
- the above results are of reference value for the future development of all-natural plant antioxidant extract ingredient products and drugs, ingredient combination, solvent selection and use of measuring tools.
- This experiment is to study the effects of different doses of the exclusive SDTL-E extract and the combination of various reagent groups on cell viability through cell experiments, in order to select and prove the optimal dosage and the best range of efficacy, and provide the best anti-oxidation for subsequent research and development. It provides references for substances, combinations and dosages, and also provides research references for related animal experiments.
- PrestoBlueTM HS cell viability reagent (Thermo Fisher Scientific) is used to measure cell viability. The principle is that Resazurin in the reagent will be reduced to red and highly fluorescent resorufin after entering living cells. °
- Cell viability was determined according to the instructions of the PrestoBlue® HS cell viability reagent supplier. In a 96-well plate (96-well plate), 10,000 cells were first prepared in each well and immersed in 90 medium. 10 PrestoBlue® HS Cell Viability Reagent was then added to the wells and placed in a dark 37°C incubator for 10 minutes. Finally, use a Microplate Reader (Molecular Devices, San Jose, California, U_S_A) to measure the Fluorescence Excitation Wavelength is 560 nm, and then measure the Fluorescence Emission Wavelength 590 nm To quantify cell viability. Evaluation procedure: 0.5 mM hydrogen peroxide (Kam Sing Medicine Co.
- the first phase of the experiment is to measure the cell viability 15 minutes after using each group of reagents to screen out the reagents with the best effect on cell viability; the second phase of the experiment is to dilute the reagents screened in the first phase to different concentrations to treat the cells for 15 minutes Then determine the cell viability to select the optimal dose of each group of reagents; in the third stage, the best reagents selected in the first and second stages are used to treat the cells at the optimal dose for 15 minutes and then measure the cell viability. capabilities for further comparison.
- 0.1%-0.9% concentration A significantly increased the viability of damaged cells by 190%
- 1%-5% concentration A significantly increased the viability of damaged cells by 126% (p ⁇ 0.05).
- 0.1%- 0.9% concentration B significantly increased the viability of damaged cells by 158%
- 1%-5% concentration B significantly increased the viability of damaged cells by 99%.
- 0.1%-0.9% concentration D increased the viability of damaged cells by 79%
- 1%-5% concentration D increases
- Attachment 2 Figure 3 After being treated with different concentrations of A, B, and D reagent groups for 15 minutes, the % change in cell viability of cells relative to the normal control group (represented by the red dotted line) Note 1: The red line is the viability level of the normal cell control group. Note 2: All reagents are diluted in cell culture medium. Note 3: * indicates a significant statistical difference (p ⁇ 0.05) compared with the normal cell control group. Attachment 2 Figure 4. After being treated with reagent groups A, B, and D at different concentrations for 15 minutes, the % change of cell viability compared to the damaged cell control group (represented by the red dotted line) Note 1: The red line is the level of the damaged cell viability of the control group.
- Reagent B at 0.1%-0.9% concentration significantly increased the viability of damaged cells by 198% (p ⁇ 0.05).
- 0.1%-0.9%% concentration D reagent significantly increased the viability of damaged cells by 198% (p ⁇ 0.05).
- Reagent C at a concentration of 0.1%-0.9% significantly increased the viability of damaged cells by 176% (p ⁇ 0.05).
- Table 3, Annex II Figure 6 The above experimental results show that reagent A at a concentration of 0.1%-0.9% is the best in increasing the viability of normal or damaged cells, while reagent C has no obvious effect on increasing the viability of normal cells, but it can significantly increase the viability of damaged cells. .
- H 2 0 2 Hydrogen peroxide is a kind of active oxygen, which can cause oxidative damage to cells and destroy cell viability, and has been widely used in the past research to establish HUVEC injury cell model [2].
- hydrogen peroxide significantly reduced the viability of HUVEC cells by more than 70% on average, and successfully established the damaged cell model.
- the results of the first phase of the experiment showed that each reagent group improved and enhanced the viability of damaged cells as a whole, but did not improve or enhance the viability of normal cells as a whole, indicating that each reagent group only acts on damaged cells.
- each reagent group has no obvious effect on improving and enhancing the vitality of normal cells, but only has an effect on improving the vitality of damaged cells, and the greater the damage to the cells, the greater the effect of each reagent group on the repair of damaged cells. The stronger the effect on improving vitality.
- oil-soluble reagents are stronger than water-soluble reagents, and reagent A has the highest and most significant ability to improve and enhance the viability of damaged cells.
- Reagents A, B, and D had no significant effect on the viability of normal cells in the first phase of the experiment, but significantly increased the viability of normal cells in the third phase of the experiment.
- the average viability value of the normal cell control group (Appendix Table 3) is much lower than the average viability value of the normal cell control group in the first stage experiment (Appendix Table 1), which may be due to unknown reasons during the third stage of cell culture For example, free radicals produced by environmental chemical pollutants can cause oxidative damage to cells and destroy cell viability [3].
- the experimental results showed that the biological effects of each group of reagents on normal cells were limited, and the data were not statistically significant. The experimental results also show that each group of reagents has a significant effect on the damaged cells, and when the damage to the cells themselves is greater,
- Reagent groups A, B, and D have more significant effects on cell repair and improvement of viability.
- the results show that the special SDTL-E extract and
- the 0.1%-0.9% concentration of D reagent was the second most effective in improving and enhancing the viability of damaged cells, reaching 198% compared with damaged cells.
- the 0.1%-0.9% concentration of reagent B can improve and enhance the viability of damaged cells, which is 198% higher than that of damaged cells.
- the 0.1%-0.9% concentration of C reagent was the second most effective in improving and enhancing the viability of damaged cells, which was 176% compared to the damaged cells.
- reagents A, B and D could all reduce the level of reactive oxygen species in damaged cells, and reagents A, B and D could rapidly reduce the level of reactive oxygen species in cells after treating the damaged cells for 3 minutes.
- Each reagent group treated the damaged cells for 3 minutes.
- the 0.1%-0.9% concentration of A reagent significantly reduced the reactive oxygen species in the damaged cells by 67% (p ⁇ 0.05), and the effect was the most rapid, significantly reducing and Improve the active oxygen in damaged cells most rapidly and most significantly.
- Each reagent group treated the damaged cells for 15 minutes.
- the B reagent at a concentration of 0.1%-0.9% significantly reduced the reactive oxygen species in the damaged cells by 75% (p ⁇ 0.05).
- Active oxygen has the most significant and sustained effect.
- the experimental results show that each reagent group has a significant effect of reducing active oxygen.
- the experiment has a direction for the research and development of all-natural plant antioxidant ingredients and the ingredients, combinations, dosage, antioxidant effect, antioxidant onset speed and other subsequent cell research. Inspirational significance and follow-up animal experiment reference value.
- Reactive Oxygen Species are compounds that are more reactive than molecular oxygen in chemical reactions.
- Reactive oxygen species include free radicals (Free Radical) and non-free radicals (Nonfree Radical) oxygen-containing molecules, which can lead to increased formation of reactive oxygen species and oxidative stress (Oxidative Stress) and damage redox balance.
- Hydrogen peroxide is a non-free radical active oxygen. When it accepts an extra electron, it will split into hydroxyl radical (Hydroxyl Radical) (HO ) and hydroxyl anion (OH- )[1, 2].
- Oxidative Stress can damage osteoblasts and is related to osteoporosis, while antioxidants can protect osteoblasts from oxidative damage and help control osteoporosis [4, 5].
- the cell culture method is based on the instructions of the cell supplier ATCC, and the vascular cell basal medium (ATCC) added with the endothelial cell growth medium (Endothelial Cell Growth Kit-VEGF) (ATCC) is used to culture the human umbilical vein Endothelial cells were cultured at 37°C and 5% carbon dioxide.
- ATCC vascular cell basal medium
- Endothelial Cell Growth Kit-VEGF Endothelial Cell Growth Kit-VEGF
- Intracellular ROS Assay Fluorometric Intracellular ROS Assay (Sigma Aldrich) was used to measure the content of reactive oxygen species in cells to evaluate the anti-inflammatory effects of reagents A, B, and D on cells. oxidation capacity. The principle is that intracellular
- the oxygen reacts with the cell-permeable sensor chemical (Cell-permeable Sensor Chemical) to generate light.
- Cell-permeable Sensor Chemical The stronger the antioxidant capacity of A, B, and D reagents in the cells, the lower the fluorescence brightness value will be.
- Fluorescent intracellular reactive oxygen species were measured according to the supplier's instructions. In a 96-well plate (96 Well Plate), 10,000 cells were first prepared in each well and immersed in 100 medium, and then 100 sensor reaction mixture (Reaction Master Mix) was added. , and placed at B7°C for 30 minutes. Then a microplate reader (Molecular Devices) was used to quantify intracellular reactive oxygen species with an excitation wavelength of 540 nm and an emission wavelength of 570 nm.
- the experimental groups are: normal cell control group, normal cells plus water, normal cells plus oil, normal cells plus A reagent, normal cells plus B reagent, normal cells plus D reagent, damaged cell control group, damaged cells plus water, damaged cells plus oil 12 groups including damaged cells plus A reagent, damaged cells plus B reagent and damaged cells plus D reagent.
- parametric Parametric
- t-test t-test
- Mann-Whitney test Mann-Whitneytest
- Concentration D at 0.1%-0.9% also reduced activity in injured cells Oxygen 19%.(Table 2, Figure 4)
- Table 2, Figure 4 The above experimental results show that when the 0.1%-0.9% concentration of A and B reagents treat normal and damaged cells for 3 minutes, they can rapidly and significantly reduce the level of reactive oxygen species in damaged cells and cells.
- H202 Hydrogen peroxide is a kind of reactive oxygen species, which can lead to the increase of intracellular reactive oxygen species such as superoxide anion CSeroxide anions;) [8] - produce and cause oxidative damage to cells, resulting in abnormal cell apoptosis, and have been widely used in previous studies To establish the HUVEC injury cell model[9].
- hydrogen peroxide significantly increased the reactive oxygen species in HUVEC cells by more than 90%, and the experimental results confirmed that the damaged cell model was successfully established.
- Phase 1 experiment each reagent group treated the cells for 15 minutes, showing that the A, B, and D reagents all reduced the reactive oxygen species in the damaged cells, which was statistically significant.
- Oxygen levels are strong. However, when the A and B reagents were used to treat the damaged cells for 15 minutes, the ability of B to reduce the level of reactive oxygen species in the damaged cells was stronger than that of A. Through the analysis and comparison of the two-stage experimental results, it was shown that the antioxidant effect of A on damaged cells was faster than that of B, while the antioxidant effect of B on damaged cells was stronger than that of A, but the effect was slower.
- the results of the two-stage experiment also showed that: B, D reagents treated normal cells for 3 minutes, can reduce the level of active oxygen in normal cells, but when B, D reagents treated normal cells for 15 minutes, but increased the level of intracellular active oxygen,
- B D reagents treated normal cells for 3 minutes
- the first reason is that the raw data of the experiment showed that in the second stage experiment of treating normal cells for 3 minutes, the average value of reactive oxygen species in the control group of normal cells (Appendix Table 2; ) was much higher than that of the second stage experiment of treating normal cells for 15 minutes.
- the average value of reactive oxygen species in the normal cells of the control group in the stage 1 experiment is an appendix table, which may be due to the oxidative damage to the cells caused by free radicals produced by environmental chemical pollutants during the cell culture process of the second stage experiment ⁇ 10;
- cell experiment factors may cause reactive oxygen metabolites to fail to be excreted from the body as in the physiological metabolism in the living body, thereby causing the accumulation of reactive oxygen species in cells and leading to an increase in the accumulation of reactive oxygen species in cells. Therefore, the results of cell experiments can only be used as a reference for animal experiments, and cannot fully reflect what actually occurs in animals or humans. Through this study, the experimental results and data analysis show that in this experiment, the higher the level of active oxygen in the cells, the more significant the effect of the reagent groups A, B, and D on reducing the level of active oxygen in the cells, and the more effective they are in reducing the level of active oxygen in the cells.
- Damaged cells have a strong antioxidant repair effect, but for normal cells, the effectiveness of each reagent group is limited, and the data is not statistically significant, suggesting that the significant antioxidant effect of each reagent group on normal cells and damaged cells comes from the treatment of The scavenging and regulation mechanism of reactive oxygen species in cells.
- Conclusion The experimental results clearly show that the patented SDTL-E extract and combination A, B, and D reagents have significant antioxidant effects, dose-effect, and time relationships on reactive oxygen species in damaged cells.
- the experimental results also show that each reagent group, for normal The antioxidant effect of reactive oxygen species in cells is limited, and the data is not statistically significant, but it also suggests the difference and regulation or balance effect of each reagent group on damaged and normal cells.
- each reagent group has obvious antioxidant effects on damaged cells, and when the cells themselves are more damaged, the antioxidant effects of each reagent group A, B, and D on cells are more significant, showing that each reagent group has a greater effect on cells.
- Active oxygen in damaged cells has a strong antioxidant effect.
- Each reagent group treated the damaged cells for 15 minutes, and the 0.1%-0.9% concentration of B reagent had the highest and most significant effect on reducing the reactive oxygen species in the damaged cells, which was significantly reduced by 75% compared with the damaged cells.
- the 0.1%-0.9% concentration of reagent A was the second most effective in reducing reactive oxygen species in damaged cells, and significantly reduced 68% reactive oxygen species compared with damaged cells.
- the 0.1%-0.9% concentration of D reagent reduces the effect of reactive oxygen species in damaged cells. Compared with damaged cells, the reactive oxygen species is reduced by 36%.
- Potassium lon Chaime ⁇ a potassium ion channel, is a pore across the cell membrane, which can selectively allow only potassium ions to pass through the cell membrane.
- the literature points to a potential role for modulation of potassium channels in osteoporosis and joint degeneration.
- Previous studies have also shown that potassium ion channels can affect cell proliferation cycle, cell viability, and cell apoptosis.
- the immortalized human umbilical vein endothelial cell line HUVEC was used as a model cell, and the three reagents of the patented SDTL-E extract A, B and composition D were evaluated through the determination of potassium ion channels.
- the experimental results showed that A, B, and D reagents treated normal and damaged cells for 15 minutes, compared with the damaged cell control group, had very little effect on the voltage-gated potassium ion channels of normal and damaged cells, without statistical significance.
- the experimental results show that reagents A, B, and D all have significant effects on down-regulating the activity of non-voltage-gated potassium ion channels in normal and damaged cells, but have no obvious effect on voltage-gated potassium ion channels, indicating that their mechanism of action is through non-voltage-gated potassium ion channels. It is presented by controlling potassium ion channel pathway.
- the experimental results show that there is a significant difference in the activity of the voltage-gated potassium ion channel between the single extract and the extract composition, and the
- the cell culture method is based on the instructions of the cell supplier ATCC, and the vascular cell basal medium (ATCC) added with the endothelial cell growth medium (Endothelial Cell Growth Kit-VEGF) (ATCC) is used to culture the human umbilical vein Endothelial cells were cultured at 37°C and 5% carbon dioxide.
- Counting Cell Numbers A Hemocytometer (Paul Marienfeld GmbH & Co. KG, Lauda-Konigshofen, Germany) was used to count the cell numbers. 10 piL of cells were injected into a hemocytometer, which was then placed under a cell culture microscope (Thermo Fisher Scientific, Waltham, Massachusetts, USA) to count the number of cells. Potassium Ion Channel Assay
- FluxORäll green ion channel assay (Thermo Fisher Scientific) was used to measure the activity of ion channels in cells to evaluate the effects of reagents A, B, and D on the activity of potassium ion channels in cells.
- the principle is to use Thallium Ion, which can enter the cell through the potassium ion channel.
- the Thallium ion enters the cell and reacts with the FluxORTMll Green Indicator Dye (FluxORTMll Green Indicator Dye) placed in the cell beforehand, it will emit green light.
- FluxORTMll Green Indicator Dye FluxORTMll Green Indicator Dye
- Potassium ion channels were determined according to the supplier’s instructions for FluxORäll green potassium ion channel assays. In a 96-well plate (96 Well Plate), 20,000 cells were prepared in each well and immersed in 80 medium, and then 80 FluxORäll green indicators were added. Dye and place at 24°C for 60 minutes.
- Non-Voltage Gated Potassium Ion Channel (Non-Voltage Gated Potassium Ion Channel)
- Basal Potassium Stimulus Buffer containing thallium ions Ion channel activity (Voltage-Gated Potassium Ion Channel )
- High Potassium Stimulus Buffer containing thallium ions 40 piL of High Potassium Stimulus Buffer containing thallium ions.
- a microplate reader (Molecular Devices) was used to measure the light, the light excitation wavelength was 490 nm, and then the fluorescence emission wavelength was measured at 525 nm to quantify the cellular potassium ion channel activity. Evaluation procedure 0.5 mM hydrogen peroxide (Kam Sing Medicine Co.
- vascular cell basal medium was added to HUVEC cells for 30 minutes in the normoxic cell control group). Then add the vascular cell basal medium and reagents A, B, and D diluted to 0.1%-0.9% concentration by the vascular cell basal medium into the damaged cell control group and the normal cell control group for 15 minutes, respectively. Then through potassium ion channel measurement, value acquisition, statistics, and analysis of the effects and differences of various reagents on cellular potassium ion channel activity.
- the experimental groups are: normal cell control group, normal cell plus water, normal cell plus fat, normal cell plus A reagent, normal cell plus B reagent, normal cell plus D reagent, damaged cell control group, damaged cell plus water, damaged cell Add oil, add A reagent to damaged cells, add B reagent to damaged cells, and add D reagent to damaged cells, a total of 12 groups.
- Statistical Analysis The study was performed in two phases. Experiments at each stage were repeated 3 times, and then different groups of cells, control group and damaged cells were
- the first phase of the experiment was to measure the activity of non-voltage-gated potassium ion channels in normal and damaged cells 15 minutes after using each group of reagents; the second phase of the experiment was to measure the voltage-gated potassium in normal and damaged cells 15 minutes after using each group of reagents ion channel activity.
- the experimental results showed that compared with the control group of damaged cells, the concentration of A at 0.1%-0.9% significantly reduced the activity of non-voltage-gated potassium ion channels in damaged cells by 54% (p ⁇ 0.05) and the concentration of B at 0.1%-0.9% significantly reduced the activity of damaged cells
- the activity of non-voltage-gated potassium ion channels was 65% (p ⁇ 0.05), and the concentration of 0.1%-0.9% D significantly reduced the activity of non-voltage-gated potassium ion channels in damaged cells.
- composition D at a concentration of 0.1%-0.9% reduces the activity of voltage-gated potassium ion channels in normal cells by a maximum of 44% (p ⁇ 0.05).
- the red line is the activity level of potassium ion channel in normal cells in the control group.
- Note 2 All reagents are diluted to 0.1%-0.9% with cell culture medium, and the concentration of water is 1%-5%.
- Attachment 4 Figure 2 After being treated with each reagent for 15 minutes , the % change of intracellular potassium ion channel activity relative to the damaged cell control group (represented by the red dotted line).
- the red line is the activity level of potassium ion channel in the damaged cell control group.
- Note 2 All The reagent is diluted to 0.1%-0.9% with cell culture medium, and the concentration of water is 1%-5%.Note 3: * means there is a significant statistical difference compared with the damaged cell control group (p ⁇ 0.05).
- 5Kosan potassium ion channels can be divided into different subfamilies (Subfamily) according to their structure and function, such as inward rectifier (Inward rectifier)
- Rectifiers Four Transmembrane Segments-2 Pores (FourTransmembrane Segments-2 Pores, K2P), Voltage-gated (Voltage-
- Cilantro Leaf Extract can reduce, Voltage dependence of activation of the voltage-gated ion channel KCNQ2/B [knife. Based on the results of previous experiments on the activity of A, B, and D reagents, this experiment confirmed that A, B, and D reagents all exhibit biological effects through the non-voltage-gated potassium ion channel pathway.
- Hydrogen peroxide is a kind of reactive oxygen species, which has been widely used to establish HUVEC injury cell models in previous studies [8], and can increase the activity of potassium ion channels [9].
- hydrogen peroxide significantly increased the activity of non-voltage-gated potassium ion channels in HUVEC cells by 71%, and the experimental results confirmed that the damaged cell model was successfully established.
- Phase 1 experiment Each reagent group treated the cells for 15 minutes, showing that ⁇ A, B, and D reagents all significantly reduced the activity of the non-voltage-gated potassium ion channel of the damaged cells, with statistical significance.
- B and D reagents also significantly reduced the activity of non-voltage-gated potassium ion channels in normal cells. Although reagent A also reduced the activity of non-voltage-gated potassium channel in normal cells, it was not statistically significant. The experimental results show that the B reagent has the strongest and most significant effect in reducing the activity of the non-voltage-gated potassium ion channel when the injured cells are treated for 15 minutes.
- Phase 2 experiment Each reagent group treated the cells for 15 minutes and showed that A and B reagents (extracts had an effect on the activity of voltage-gated potassium ion channels in damaged cells, but there was no statistical significance, only D reagent (extract composition) Compared with the normal cell voltage-gated potassium ion channel activity value, it has statistical significance, showing that the extraction composition D and single extracts A and B have differences in the regulation of normal cell voltage-gated potassium ion channels.
- Single extracts A, Reagent B showed an increase in the activity of voltage-gated potassium ion channels in damaged cells, while reagent D of the extract composition showed a decrease in the activity of voltage-gated potassium ion channels in damaged cells.
- Past research literature has shown that hydrogen peroxide can increase the magnitude of calcium-activated potassium currents in HUVEC cells [9], reflecting that hydrogen peroxide increases cellular calcium and activates potassium ion channel activity.
- Another research literature shows that plant phenolic compounds can inhibit calcium and activate potassium channels [10].
- calcium-activated potassium channels are traditionally regarded as voltage-gated potassium channels, some literatures have pointed out that some voltage-gated potassium channels can also be regulated by ligand-gated potassium channels by directly combining with plant extracts[ 7].
- Previous research literature pointed out that among potassium ion channels, voltage-gated potassium ion channels are the main regulatory mechanism of cell viability, cell proliferation and cell death [4, 5].
- A, B, and D reagents can improve the results of HUVEC cell viability and analyze the results of this experiment.
- the results of this experiment show that in this experiment, A, B, and D reagents Regardless of whether it is normal or damaged cells, the effect on the activity of non-voltage-gated potassium ion channels is significant, while the effect on the activity of voltage-gated potassium ion channels is limited, and the data are not statistically significant, suggesting that each reagent group is passed through Regulation of non-voltage-gated potassium ion channels to exhibit functional effects on normal cells and damaged cells is to regulate cell viability through non-voltage-gated potassium ion channels.
- Reagent A at a concentration of 0.1%-0.9% reduces the activity of non-voltage-gated potassium ion channels in damaged cells, which is 54% lower than that of damaged cells.
- Each reagent group treated the damaged cells for 15 minutes, and the activity of the reagents on the voltage-gated potassium channel of the damaged cells was not statistically significant.
- 0.1%-0.9% concentration of A increased the activity of voltage-gated potassium ion channels in injured cells by 32%.
- Concentration B at 0.1%-0.9% increased the activity of voltage-gated potassium ion channels in damaged cells by 12%.
- D at a concentration of 0.1%-0.9% reduced the activity of voltage-gated potassium ion channels in damaged cells by 28%.
- composition D shows the difference between composition D and extracts A and B due to the complex action.
- the comprehensive literature data and the results of this experiment show that SDTL-E exclusive extracts A, B and composition D all regulate cells by affecting non-voltage-gated potassium ion channels.
- the above experimental results on normal cells and damaged cells are of inspiration and reference value for the further development and development of all-natural plant antioxidant extract products and components, combinations, dosage, and understanding of the mechanism of action on the activity of potassium ion channels.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023574711A JP2024520721A (ja) | 2021-05-30 | 2022-05-30 | 関節変性及び骨粗鬆症を治療する皮膚外用天然エキス及び方法 |
CA3221031A CA3221031A1 (en) | 2021-05-30 | 2022-05-30 | External skin application of articles and manufacturing methods for treating joint degenerative arthritis and osteoporosis using natural extracts |
KR1020237045437A KR20240027629A (ko) | 2021-05-30 | 2022-05-30 | 피부외용 관절 퇴화 및 골다공증 치료 천연추출물 및 방법 |
CN202280050350.1A CN117940143A (zh) | 2021-05-30 | 2022-05-30 | 皮肤外用治疗关节退化及骨质疏松症的天然提取物与方法 |
EP22815452.2A EP4378470A1 (en) | 2021-05-30 | 2022-05-30 | Topical natural extract for skin for treatment of joint degeneration and osteoporosis and method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163195054P | 2021-05-30 | 2021-05-30 | |
US63/195,054 | 2021-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022254316A1 true WO2022254316A1 (zh) | 2022-12-08 |
Family
ID=84322567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2022/055058 WO2022254316A1 (zh) | 2021-05-30 | 2022-05-30 | 皮膚外用治療關節退化及骨質疏鬆症的天然提取物與方法 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4378470A1 (zh) |
JP (1) | JP2024520721A (zh) |
KR (1) | KR20240027629A (zh) |
CN (1) | CN117940143A (zh) |
CA (1) | CA3221031A1 (zh) |
WO (1) | WO2022254316A1 (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1439377A (zh) * | 2002-02-21 | 2003-09-03 | 北京龙兴科技股份有限公司 | 一种改善骨质疏松的组合物 |
CN101919888A (zh) * | 2010-01-18 | 2010-12-22 | 上海交通大学医学院 | 胡萝卜提取物及其制备方法和应用 |
CN105267270A (zh) * | 2014-06-24 | 2016-01-27 | 株式会社诺薇雅 | 皮肤外用剂 |
CN111163797A (zh) * | 2017-08-21 | 2020-05-15 | 伦萨有限责任公司 | 组合物和由其制备的营养补剂 |
CN111818899A (zh) * | 2018-03-12 | 2020-10-23 | 奇华顿股份有限公司 | 包含岩兰草根提取物的化妆品组合物 |
-
2022
- 2022-05-30 CA CA3221031A patent/CA3221031A1/en active Pending
- 2022-05-30 EP EP22815452.2A patent/EP4378470A1/en active Pending
- 2022-05-30 JP JP2023574711A patent/JP2024520721A/ja active Pending
- 2022-05-30 WO PCT/IB2022/055058 patent/WO2022254316A1/zh active Application Filing
- 2022-05-30 KR KR1020237045437A patent/KR20240027629A/ko unknown
- 2022-05-30 CN CN202280050350.1A patent/CN117940143A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1439377A (zh) * | 2002-02-21 | 2003-09-03 | 北京龙兴科技股份有限公司 | 一种改善骨质疏松的组合物 |
CN101919888A (zh) * | 2010-01-18 | 2010-12-22 | 上海交通大学医学院 | 胡萝卜提取物及其制备方法和应用 |
CN105267270A (zh) * | 2014-06-24 | 2016-01-27 | 株式会社诺薇雅 | 皮肤外用剂 |
CN111163797A (zh) * | 2017-08-21 | 2020-05-15 | 伦萨有限责任公司 | 组合物和由其制备的营养补剂 |
CN111818899A (zh) * | 2018-03-12 | 2020-10-23 | 奇华顿股份有限公司 | 包含岩兰草根提取物的化妆品组合物 |
Non-Patent Citations (3)
Title |
---|
JIN, YUNRONG: "Vetivert", THE COMPLETE BOOK OF ESSENTIAL OILS, 30 June 2020 (2020-06-30) * |
LI LU: "Association between Carotenoid Intake and Osteoporosis", MASTER'S THESES OF JILIN UNIVERSITY, 15 November 2019 (2019-11-15), XP093009851 * |
WANG, YUZHEN: "Choose the best food for anti-aging and anti-aging", FAMILY & TRADITIONAL CHINESE MEDICINE, no. 8, 31 August 2007 (2007-08-31), pages 70 - 72, XP009541665, ISSN: 1005-3743 * |
Also Published As
Publication number | Publication date |
---|---|
JP2024520721A (ja) | 2024-05-24 |
CN117940143A (zh) | 2024-04-26 |
EP4378470A1 (en) | 2024-06-05 |
KR20240027629A (ko) | 2024-03-04 |
CA3221031A1 (en) | 2022-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ham et al. | Effects of long‐term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys | |
Sun et al. | The effects of combined treatment with naringin and treadmill exercise on osteoporosis in ovariectomized rats | |
Dalais et al. | The effects of soy protein containing isoflavones on lipids and indices of bone resorption in postmenopausal women | |
Leung et al. | Herbal treatment for osteoporosis: a current review | |
Shen et al. | Green tea polyphenols attenuate deterioration of bone microarchitecture in female rats with systemic chronic inflammation | |
He et al. | Osteoprotective effect of extract from Achyranthes bidentata in ovariectomized rats | |
Choi et al. | Ultrafine Angelica gigas powder normalizes ovarian hormone levels and has antiosteoporosis properties in ovariectomized rats: particle size effect | |
Cho et al. | A synergistic bone sparing effect of curcumin and alendronate in ovariectomized rat | |
CN109745330A (zh) | 齐墩果酸和熊果酸在制备调节维生素d3代谢酶活性的药物中的应用 | |
Guerra et al. | Modulation of bone turnover by Cissus quadrangularis after ovariectomy in rats | |
Lee et al. | Effect of a bisphosphonate and selective estrogen receptor modulator on bone remodeling in streptozotocin-induced diabetes and ovariectomized rat model | |
Dong et al. | A high-saturated-fat, high-sucrose diet aggravates bone loss in ovariectomized female rats | |
Gennari et al. | Bazedoxifene for the prevention of postmenopausal osteoporosis | |
Shen et al. | Safety and efficacy of tocotrienol supplementation for bone health in postmenopausal women: protocol for a dose–response double-blinded placebo-controlled randomised trial | |
WO2022254316A1 (zh) | 皮膚外用治療關節退化及骨質疏鬆症的天然提取物與方法 | |
Dog et al. | An integrative approach to menopause | |
Malik et al. | Combined virgin coconut oil and tocotrienol-rich fraction protects against bone loss in osteoporotic rat model | |
Naghsh et al. | The effect of Nigella sativa (black seed) supplementation on body weight and body composition: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials | |
Liyanage et al. | Effect of vitamin D therapy on bone mineral density in patients with diabetic nephropathy; a randomized, double-blind placebo controlled clinical trial | |
Kang et al. | Selection of the optimal herbal compositions of red clover and pomegranate according to their protective effect against climacteric symptoms in ovariectomized mice | |
EP3009013A1 (en) | Therapeutic and nutritional compositions for functional gastrointestinal disorders | |
Shih et al. | Topical application of the plant extract SDTL-E in ovariectomized rats: A potential new approach for treating osteoporosis | |
MacNicol et al. | The influence of a simulated digest of an equine dietary feed additive G's formula on contractile activity of gastric smooth muscle in vitro | |
Javidi et al. | Achievements in Hypothyroidism Treatment with Herbal Medicine: A Systematic Review of Randomized Controlled Trials | |
Xu et al. | Phytotherapy versus hormonal therapy for postmenopausal bone loss: a meta-analysis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22815452 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023574711 Country of ref document: JP Ref document number: 3221031 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022815452 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280050350.1 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2022815452 Country of ref document: EP Effective date: 20240102 |
|
ENP | Entry into the national phase |
Ref document number: 2022815452 Country of ref document: EP Effective date: 20240102 |